TARRYTOWN, N.Y. & RALEIGH, N.C.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that they have entered into an exclusive ...

TARRYTOWN, N.Y., May 20, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today provided analyses of safety and efficacy endpoints from the 1,034-patient, one-year phase 3 safety ...

Progenics Pharmaceuticals announced that it will hand over commercial duties on Relistor, a subcutaneous injection for opioid-induced constipation (OIC), to Salix, beginning in April. Financial terms ...

TARRYTOWN, N.Y. & COLLEGEVILLE, Pa. -- April 25, 2008 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food ...

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced the Therapeutic Goods Administration (TGA) division of the Australian Government has approved the ...

BEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence ...

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) under ...

Progenics stands to earn almost $70 million during one-year transition period and to support development of Relistor. Progenics Pharmaceuticals is to regain all rights to the marketed drug Relistor® ...

TARRYTOWN, N.Y., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. PGNX today received a $40 million milestone payment from its worldwide collaboration partner, Salix Pharmaceuticals, ...

Salix Pharmaceuticals SLXP and Progenics Pharmaceuticals PGNX today announced that the FDA is seeking input from an Advisory Committee on Salix's Supplemental New Drug Application (sNDA) for RELISTOR® ...